MedTrace Logo

A Study of NDI 1150-101 in Patients With Solid Tumors

NCT05128487 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2024-11-25

No results posted yet for this study

Summary

This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.

Conditions

Interventions

DRUG

NDI-101150

NDI-101150 capsules

DRUG

Pembrolizumab

Pembrolizumab IV infusion

Sponsors & Collaborators

  • Nimbus Saturn, Inc.

    lead INDUSTRY

Principal Investigators

  • Anita Scheuber, MD · Nimbus Saturn

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-05
Primary Completion
2025-02-28
Completion
2025-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05128487 on ClinicalTrials.gov